In April 2013 the annual European Group for Blood and Marrow Transplantation (EBMT) conference will be held in London. As part of this conference, there is a dedicated Patient and Family Day on Saturday 6 April where the content is geared towards people who have had a bone marrow transplant – and of course their families.

Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation
Blood. 2012 Aug 15;[Epub Ahead of Print], J Cortes, JH Lipton, D Rea, R Digumarti, C Chuah, N Nanda, AC Benichou, AR Craig, M Michallet, FE Nicolini, H Kantarjian

With an FDA filing of its wholly owned chronic myelogenous leukemia drug ponatinib under its belt, Ariad Pharmaceuticals Inc.says it will be commercially ready in the U.S. by the end of October and hopes to launch in the first quarter of 2013.

Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells
Br J Cancer. 2012 May 1;1061772-1778, J Wang, TP Hughes,

Thanks to Andrew Schorr of Patient Power who produced the following video interview with Brian Druker MD.

'Results from the ongoing Phase 2 PACE trial of ponatinib reported in June at this year’s annual meeting of the American Society of Clinical Oncology showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the PACE trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD’s Phase 3 EPIC trial comparing ponatinib to imatinib that is now underway in newly diagnosed chronic-phase CML patients.

New Data Confirm Safety of Stopping Imatinib in Leukemia
IMNG Medical Media. 2012 Jun 26, S Freeman

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 27, 2012--

Leukemia. 2012 Mar 26. doi: 10.1038/leu.2012.85. [Epub ahead of print]

Leukemia advance online publication
15 June 2012; doi: 10.1038/leu.2012.134